European Commission Closes Sanofi Disparagement Case on Commitments

The European Commission has closed its disparagement case against Sanofi, accepting commitments from the pharmaceutical group rather than pursuing an infringement finding. The decision ends the inquiry without a fine. The Commission confirmed the closure in a statement reported by Lexology under the headline "Commission closes Sanofi disparagement case with commitments".

The case is the latest chapter in the Commission's enforcement interest in pharmaceutical disparagement, a theory of abuse under Article 102 TFEU that has gathered pace since the late 2010s. Disparagement, in this context, means a dominant company spreading misleading or unfounded claims about a competitor's product, typically to slow its uptake and protect its own revenue.

What did the Commission decide?

The Commission settled. That carries a precise procedural meaning under EU competition law: the regulator has concerns, the company offers remedies, and the regulator makes those remedies binding without establishing an infringement.

Under Article 9 of Regulation 1/2003, a commitments decision does not conclude that an abuse occurred. Sanofi admits nothing. The commitments nonetheless bind the company, and the Commission can impose a fine of up to 10 per cent of worldwide group turnover if the company breaches them.

The Commission has not imposed a penalty. No finding of infringement appears in the closure. That distinction will matter to litigators on both sides.

For context on scale: a company facing a full Article 102 infringement decision risks a fine of up to 10 per cent of global turnover, which for a pharmaceutical group of Sanofi's size would mean several billions of euros. A commitments decision caps that exposure at zero. The remedy, not the money, is the story.

Why does disparagement matter in pharma?

The Commission has treated disparagement as a serious concern in the medicines sector, where a dominant incumbent may have both the motive and the platform to cast doubt on a challenger's therapy.

The mechanism is simple. If clinicians hear repeated safety doubts about a rival drug, even unfounded ones, prescribing behaviour shifts. Delays of even a few months in adoption can be worth hundreds of millions of euros for a blockbuster medicine, given that annual sales for leading biologics routinely exceed one billion euros.

The concern is not hypothetical. The Commission fined Teva 462.6 million euros in October 2024 for disparaging Copaxone, its own multiple sclerosis medicine, to hold off competition from generic versions. That case signalled a regulator prepared to treat denigration campaigns as hard-core abuse rather than as soft regulatory noise. The Sanofi closure, by contrast, shows the other route: the Commission accepting binding behavioural fixes.

What do commitments decisions mean for practitioners?

Three practical consequences follow.

• No precedent on the merits. A settlement means no infringement finding, so the decision offers guidance on acceptable remedies rather than a litigated definition of abuse. Claimants in follow-on damages actions cannot rely on it as proof of wrongdoing.
• The commitments bind. Whatever Sanofi has undertaken, breach would expose the group to penalty payments. Compliance teams will need to police the commitments for their duration, likely across all EU member states.
• Sector-wide signal. Every pharma legal department in Europe will now read the accepted commitments as a template for what the Commission expects: no unfounded safety claims about rival products, no selective citation of adverse-event data, and a clean separation between scientific communication and commercial positioning.

Is the Commission's settlements strategy widening?

The pattern is discernible. The Commission has shown a growing willingness to resolve complex competition cases through Article 9 commitments rather than contested decisions, particularly where markets move faster than litigation.

For companies, the arithmetic is straightforward. A commitments decision removes fine exposure, avoids a finding that could anchor private damages claims across 27 member states, and ends the reputational drip of a multi-year probe. In exchange, the company accepts conduct restraints drafted by the regulator and supervised indefinitely.

For complainants, the arithmetic runs the other way. A rival that spent years pushing the case receives remedies but no infringement ruling, which weakens any private enforcement sequel. Settlements, in short, reward the investigated and under-reward the accuser.

What is the takeaway?

The Commission has closed its Sanofi disparagement case on binding commitments, without a fine and without an infringement finding. The message to dominant pharma groups is plain: the Commission will act on denigration, but it will also deal.